Saphris

Discussion in 'Merck' started by Anonymous, Dec 7, 2010 at 9:19 PM.

  1. Anonymous

    Anonymous Guest

    How much longer before the entire Saphris force is jettisoned?
     
  2. Anonymous

    Anonymous Guest

    Clearly we are in countdown mode, its only a matter of time.
    probably fold Saphris in with another product initially cutting out the need for Neuro Spec field force, then maybe give to a contract sales force.

    There will be cuts associated with this, sooner rather than later folks, sorry.
     
  3. Anonymous

    Anonymous Guest

    Your an idiot quit spreading lies to make people nervous. No one knows when cuts are coming and who they will target. It could be any division at any time. The company is not going to walk away from selling a product in the biggest revenue generating class of meds, especially only with one year into launch. I can't stand you iditos who post crap just to make people nervous. Everyone knows today we have jobs tomorrow we may not, thats nothing new. Unless you have credible information keep your trap shut on CP.
     
  4. Anonymous

    Anonymous Guest

    HAHAHAHA, Hire to retire is right under your nose, I just love CTMs trying to hurry and cover up the crime scene, looks like the blood will be on YOUR hands loser! Grow some balls and tell your sales people to polish their resume and start looking! We have families to feed dirt bag! Hope YOU get the kool-aid spiked with arsenic!

    For those people who need to know, this hire-to-retire process is across all divisions...go to one merck and search hire to retire, you will see, the best part about this "fine" company is not only are they going to stab you in the back, but CTM's will pick their "yes men" favorites and the rest...well you get the picture
     
  5. Anonymous

    Anonymous Guest

    Sounds like FF is at it again. Please FF, tells us in the field how good this drug is? We know how Fred Hassan saved your sorry a@@ from Bayer and you got to retire under the S/P banner. We also know how great a sales person you were--so, please tell us again, how do we sell this loser?
     
  6. Anonymous

    Anonymous Guest

    <<The company is not going to walk away from selling a product in the biggest revenue generating class of meds, especially only with one year into launch.>>

    Especially with all the generics - and soon to be generics.
    Yeah, right, the company would never walk away from this drug - over a year post launch - and what is the market share?? Has it reached a steady 1% share yet?

    Open your eyes, drink a little less kool-aid, smarten - up!
     
  7. Anonymous

    Anonymous Guest

    Walk away from drug happens all the time in an industry. Might come out ahead by dumping it for a tidy sum.
     
  8. Anonymous

    Anonymous Guest

    Saphris hasnt picked up in a year, every new drug has a small window of opportunity at the start, this drug never saw it
     
  9. Anonymous

    Anonymous Guest

    Will S-P folks still be protected with the Fred H. Severance package through November 2011?
     
  10. Anonymous

    Anonymous Guest

    Yes, Legacy Schering-Plough employees will fall under the SP severance plan until January 7, 2012. 2 years from the date of the "merger" layoffs and not from "Day 1"
     
  11. Anonymous

    Anonymous Guest

    How are you certain that it is 1/7/12, and not "day 1", which would make it 11/4/11?
     
  12. Anonymous

    Anonymous Guest

    Actually, 3/9/10 was the actual "lay-off" date post merger on Day 1, you might have to factor in the 60 day WARN period
     
  13. Anonymous

    Anonymous Guest

    anyway you slice it, as far as Saphris goes - the party's over......
     
  14. Anonymous

    Anonymous Guest


    So where will the psych reps party next? No party in the neuro room either.
     
  15. Anonymous

    Anonymous Guest

    It is time everyone stops kidding themselves about this drug, it sucks, both "flavors". It is only a matter of time for all the psych reps. I hope you are ready for a transition into something else. Unfortunately, not many companies will hire you with the same cushy base you are making now. I know it sucks and the "hope" for this drug is endless but there will be an end soon. When the end will come is anyones guess, Merck may not sink much more money or time into this peice of crap.
     
  16. Anonymous

    Anonymous Guest

    You're so wrong. Fred said this is one of the 5 shining stars and I believe him. Time to get out there and sell baby, sell!
     
  17. Anonymous

    Anonymous Guest

    You're ignorant. You are only worth this much of a rebuttal because of your ignorance and lack of cogent, not hyberbolic, thought.
     
  18. Anonymous

    Anonymous Guest

    You can call it what you will. This drug has gone nowhere fast. It may have been one of the five stars before it was introduced to the market, but it is the market that determines a drugs success. If it does not sell it will be gone soon. How do you think the BOD at Merck views a drug that has had to adjust their sales forecast down 2 times in one year? It is a real pity that you and others do not realize that the writing is on the wall. When you have a mass exodus of high and low level folks getting out of this division it is time you start to really think about the future of this drug. What does it offer that the competitors don't? What is the current MS, 0.6? The brand team had forecasted a 1.99 for 2010. What gives? Good luck.
     
  19. Anonymous

    Anonymous Guest

    Well said.

    Markets define opportunity. It is a pity that in order to be promoted here you have to reflexively say "yes, yes" to everything. There is an absolute dearth of critical thinking skills amongst the management bands.
     
  20. Anonymous

    Anonymous Guest

    Would agree, but don't think people at the tippy top or on Wall Street see this as a big issue. Don't think HR does. Maybe it is not so important anymore in a publicly traded company in a regulated industry. Obama pushes higher education, but you wonder why bother when it won't get used in most U.S. jobs.
     

Share This Page